期刊
ANTIOXIDANTS & REDOX SIGNALING
卷 11, 期 9, 页码 2167-2187出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/ars.2009.2430
关键词
-
资金
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R00NS058111] Funding Source: NIH RePORTER
- NINDS NIH HHS [R00 NS058111-03, R00 NS058111] Funding Source: Medline
Current treatments for Parkinson's disease fail to modify disease progression, and the underlying pathogenic mechanisms remain elusive. The identification of specific targets responsible for disease will aid in the development of relevant model systems and the discovery of neuroprotective and neurorestorative therapies. Two promising protein candidates, alpha-synuclein and LRRK2, offer unique insight into the molecular basis of disease and the potential to intervene in pathogenesis. Although multiple lines of evidence support alpha-synuclein and LRRK2 as robust targets for therapy, the connection between protein function and neurodegeneration is unclear. Technology capable of mitigating alpha-synuclein and LRRK2 disease-associated function will ultimately be required before the true value of these proteins as therapeutic targets can be discerned. Antioxid. Redox Signal. 11, 2167-2187.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据